Trials Sponsors Conditions Drugs Pricing

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Keywords

BPDCNTagraxofuspELZONRISRegistry StudyPost AuthorizationChemotherapy

Outcome Measures

Primary Outcomes (2)

Number of Participants Achieving Complete Response After 3 Months (+/- 1 month) of Treatment
Up to Month 4
Number of Participants Experiencing Capillary Leak Syndrome
Up to Month 51

Secondary Outcomes (9)

Number of Participants Who Receive Stem Cell Transplant (SCT)
Up to Month 66
Progression-free Survival (PFS)
Up to Month 66
Overall Survival (OS)
Up to Month 66
Best Overall Response (BOR)
Up to Month 66
Duration of Response (DOR)
Up to Month 66
+4 more secondary outcomes

Study Arms (2)

Primary Cohort: Previously Untreated

Adult participants with BPDCN prescribed tagraxofusp as a first-line treatment.

Drug: Tagraxofusp

Exploratory Cohort: Relapsed/Refractory

Adult participants with BPDCN prescribed tagraxofusp who are relapsed/refractory to prior treatment.

Drug: Tagraxofusp

Interventions

TagraxofuspDrug

No study medication will be provided by the sponsor during this study.

Also known as: ELZONRIS

Exploratory Cohort: Relapsed/RefractoryPrimary Cohort: Previously Untreated

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Adult participants with BPDCN who are to be treated (or have recently started treatment) with tagraxofusp as first-line therapy according to the European Union summary of product characteristics in standard clinical practice setting across Europe. Participants who are relapse/refractory to prior treatment will also be investigated.

You may qualify if:

Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56).

Sponsors & Collaborators

Stemline Therapeutics, Inc.
Industrylead

Study Sites (41)

Medical University Innsbruck

Innsbruck, Austria

RECRUITING

Ordensklinikum Linz Krankenhaus der Elisabethinen Linz

Linz, Austria

RECRUITING

Salzburg Cancer Research Institute (SCRI)

Salzburg, Austria

RECRUITING

Medizinische Universitat Wien, Department for Internal Medicine I, Division of Hematology and Haemostaseology

MeSH Terms

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm

Interventions

tagraxofusp

Condition Hierarchy (Ancestors)

Histiocytic Disorders, MalignantNeoplasms by Histologic TypeNeoplasmsLeukemiaLymphomaHematologic NeoplasmsNeoplasms by SiteSkin NeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Medical Director
Stemline Therapeutics, Inc.
STUDY DIRECTOR

Central Study Contacts

Stemline Trials

CONTACT

1-877-332-7967 clinicaltrials@menarinistemline.com

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 20, 2026

First Posted

August 25, 2026

Study Start

June 26, 2024

Actual (reported)

Primary Completion

September 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

A Registry-study of ELZONRIS in Participants With BPDCN

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (9)

Study Arms (2)

Primary Cohort: Previously Untreated

Exploratory Cohort: Relapsed/Refractory

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (41)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (9)

Study Arms (2)

Primary Cohort: Previously Untreated

Exploratory Cohort: Relapsed/Refractory

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (41)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations